Compare Amphastar Pharmaceuticals Inc (AMPH) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Expedia Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Expedia Group Inc trades at $270.83 (market cap $32.51B). The key difference: Expedia Group Inc is far larger — about 39.4× Amphastar Pharmaceuticals Inc's market cap, and Expedia Group Inc pays a 0.65% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | EXPE | |
|---|---|---|
Market Cap | $826.08M | $32.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $301.31 |
52-Week Low | $16.87 | $178.06 |
Enterprise Value | $1.22B | $31.42B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Expedia Group (EXPE) trades at $270.83, up 1.14% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.96 exceeding expectations by 39%. Revenue growth has accelerated from $11.7B in 2022 to $14.7B in 2025, while net income margins improved to 9.81%. Recent developments include the CarTrawler acquisition and AI initiatives, positioning the company for continued travel sector leadership.
Outlook remains positive with analyst consensus target of $285.44 offering 5.4% upside. Key opportunities include travel demand recovery and operational efficiency gains, while risks involve macroeconomic sensitivity and competitive pressures. The stock presents a balanced risk-reward profile with strong institutional support and improving financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
